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Summary
Wolfram syndrome is an autosomal recessive neurode-
generative disorder characterized by juvenile-onset dia-
betes mellitus and progressive optic atrophy. mtDNA
deletions have been described, and a gene (WFS1) re-
cently has been identified, on chromosome 4p16, en-
coding a predicted 890 amino acid transmembrane pro-
tein. Direct DNA sequencing was done to screen the
entire coding region of the WFS1 gene in 30 patients
from 19 British kindreds with Wolfram syndrome. DNA
was also screened for structural rearrangements (dele-
tions and duplications) and point mutations in mtDNA.
No pathogenic mtDNA mutations were found in our
cohort. We identified 24 mutations in the WFS1 gene:
8 nonsense mutations, 8 missense mutations, 3 in-frame
deletions, 1 in-frame insertion, and 4 frameshift muta-
tions. Of these, 23 were novel mutations, and most oc-
curred in exon 8. The majority of patients were com-
pound heterozygotes for two mutations, and there was
no common founder mutation. The data were also an-
alyzed for genotype-phenotype relationships. Although
some interesting cases were noted, consideration of the
small sample size and frequency of each mutation in-
dicated no clear-cut correlations between any of the ob-
served mutations and disease severity. There were no
obvious mutation hot spots or clusters. Hence, molec-
ular screening forWolfram syndrome in affected families
and for Wolfram syndrome–carrier status in subjects
with psychiatric disorders or diabetes mellitus will re-
quire complete analysis of exon 8 and upstream exons.
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Introduction
Wolfram syndrome (MIM 222300) is the inherited as-
sociation of juvenile-onset diabetes mellitus with optic
atrophy (Wolfram and Wagener 1938). It is also known
by the acronym “DIDMOAD” (diabetes insipidus, di-
abetes mellitus, optic atrophy, and deafness). It is a pro-
gressive neurodegenerative disorder, and many patients
also develop urinary-tract atony, ataxia, peripheral neu-
ropathy, and psychiatric illness. We previously charac-
terized the natural history of this condition in a U.K.
nationwide series of 45 patients (Barrett et al. 1995).
The minimum diagnostic criteria for this condition are
juvenile-onset diabetes mellitus and optic atrophy, which
presented at median ages of 6 years and 11 years, re-
spectively. Of these, 33 patients (73%) developed cranial
diabetes insipidus, and 28 patients (62%) presented with
sensorineural deafness in the 2d decade. Renal tract ab-
normalities were observed in 26 patients (58%) in the
3d decade, and neurological complications (cerebellar
ataxia, myoclonus) presented in 28 patients (62%) in
the 4th decade. The median age at death was 30 years
(range 25–49 years). On the basis of this study, the prev-
alence of this autosomal recessive syndrome was esti-
mated at ∼1/770,000 in the United Kingdom, with a
carrier frequency of 1/354. The prevalence has been es-
timated at ∼1/100,000 in a North American population,
on the basis of the 1/175 occurrence of optic atrophy in
a juvenile-onset diabetes clinic (Fraser and Gunn 1977).
Although Wolfram syndrome is rare, heterozygote car-
riers have been reported as 26 times more likely to re-
quire hospitalization for psychiatric illness, leading to
the hypothesis that heterozygosity for Wolfram syn-
drome gene mutations may be a significant cause of psy-
chiatric illness in the general population (Swift et al.
1998). An increased prevalence of diabetes mellitus in
first-degree relatives has also been reported (Fraser and
Gunn 1977).
A search for mutations in the mitochondrial genome,
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Figure 1 Hypothetical structure of the Wolframin protein, and positions of mutations detected in British families. The amino acid sequence
of Wolframin (GenBank accession number Y18064 ) was analyzed for hydrophobicity with the transmembrane prediction program, TMpred.
The best prediction for the sequence is schematically represented in the figure above. Grey circles denote hydrophilic domains, and the unblackened
circles denote the best-predicted transmembrane domains. Blackened circles denote amino acid residues that were deleted or mutated to STOP
codons, or sites of missense mutations in the present study. Residue 611 is highlighted by dark grey. The region of Wolframin that was found
to have homology to the prenyltransferase a-subunit repeat structure has been circled (residues 393–402).
initiated as a result of the observed similarity in phe-
notype to patients with defects of oxidative phosphor-
ylation, yielded contradictory results (Bundey et al.
1992; Jackson et al. 1994; Barrientos et al. 1996). Ge-
netic-linkage studies linked Wolfram syndrome to the
short arm of chromosome 4 (4p16) (Polymeropoulos et
al. 1994; Collier et al. 1996). The gene, WFS1/Wolfra-
min, was recently identified by Inoue et al. (1998) and
Strom et al. (1998) and was found to consist of eight
exons encompassing 33.4 kb genomic DNA encoding a
polypeptide of 890 amino acids with an apparent mo-
lecular mass of 100 kD. Hydrophobicity analysis sug-
gested a transmembrane protein comprising three struc-
tural domains; a hydrophilic amino terminus separated
from a hydrophilic COOH tail by a hydrophobic region
containing nine predicted transmembrane segments (fig.
1; TMpred). These two studies identified loss-of-func-
tion mutations in affected individuals in a total of 12
families screened, with no apparent phenotype-genotype
correlation and an absence of mitochondrial genome
abnormalities.
In the present study, we performed mutational analysis
of the WFS1 gene and mitochondrial genome in 30 pa-
tients from 19 British Wolfram kindreds, the largest co-
hort of patients studied to date. We aimed to define the
spectrum of WFS1 mutations in our population, to cor-
relate these mutations with the clinical findings in our
patients, and to determine whether a molecular genetic
screening strategy for predictive use in apparently un-
affected siblings from Wolfram syndrome families would
be feasible.
Patients and Methods
Patients
Patients for this study were selected on the basis of
(a) availability of DNA, (b) previous inclusion in a U.K.
national cohort (Barrett et al. 1995), and (c) inclusion
in a previous genetic linkage study (Collier et al. 1996).
Patients were recruited from major referral centers, a
national DIDMOAD register set up under the auspices
of The British Diabetic Association, and The British
Neurological Surveillance Unit. Minimal ascertainment
criteria were juvenile-onset (age !30 years) diabetes mel-
litus and optic atrophy. These criteria were chosen be-
cause they were the only features consistently present
and were the earliest to develop in 166 of 168 case
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reports (Blasi et al. 1986). All patients were visited at
home, for clinical history taking, examination, and
blood sampling for DNA extraction. Each patient’s hos-
pital record was also examined, then follow-up visits
were arranged to initiate further investigations. All pa-
tients were examined, with pupils dilated, by experi-
enced ophthalmologists. Studies were carried out with
the informed consent of each patient and with the ap-
proval of the regional ethics committee. Blood was
drawn from a member of staff, for DNA extraction, to
act as a normal control for sequencing analysis. Poly-
morphisms and missense mutations were screened
against a panel of 128 CEPH normal alleles.
DNA Extraction
Blood samples were obtained from all available family
members after informed consent was given. Genomic
DNA was extracted from whole blood with use of Pur-
egene DNA extraction kits (Gentra Systems), according
to the manufacturer’s instructions, and diluted to stock
solutions of 500 ng/ml.
PCR Amplification and Sequencing of the WFS1 Gene
Exons 2–8 of the WFS1 gene were amplified with a
combination of 11 primer pairs (Inoue et al. 1998). PCR
reactions were performed in a 20-ml vol containing
200–500 ng DNA, 6 pmol each of forward and reverse
primer, 200 mM dATP, dTTP, dGTP, and dCTP (Phar-
macia), 1# PCR buffer (20 mM Tris-HCl [pH 8.4] and
50 mM KCl) (Gibco-BRL), 1.5 mM MgCl2, and 1 U of
AmpliTaq polymerase (PE Biosystems). After an initial
denaturation step of 94C for 5 min, reactions were cy-
cled at 94C for 30 s, 60C for 30 s, and 72C for 30 s
for 35 cycles, with a final extension step of 72C for 10
min in a Hybaid Omnigene PCR machine. Unincorpor-
ated dNTPs and primers were removed by treatment of
5–10 ml PCR reactions with 10 U of exonuclease I and
2 U of shrimp alkaline phosphatase (PCR Product Pre-
Sequencing kit, Promega) for 15 min at 37C, followed
by 80C for 15 min. Sequencing reactions were per-
formed with either the original amplification primers or
with M13–21 forward primer (5′-TGTAAAACGACG-
GCCAGT-3′) or M13 reverse primer (5′-CAGGAAAC-
AGCTATGACC-3′), which had been engineered into the
5′ ends of the PCR primers (Inoue et al. 1998). Reactions
containing 2 ml purified PCR product, 5 pmol primer,
and 4 ml dRhodamine dye terminator reaction mix (PE
Biosystems), in a final vol of 10 ml, underwent 25 cycles
each, consisting of 96C for 30 s, 50C for 15 s, and
60C for 4 min. PCR DNA was precipitated with 0.1
vol of 3M sodium acetate (pH 4.6) and 2.5 vol of 95%
ethanol on ice for 10 min, followed by centrifugation at
13,000 rpm for 30 min. DNA pellets were washed with
70% ethanol, dissolved in 2 ml loading buffer (83%
deionized formamide, 4.1mM EDTA [pH 8.0], and 8.3
mg/ml dextran blue), and sequences were generated and
analyzed on an ABI 377 Gene Sequencer according to
the manufacturer’s instructions (PE Biosystems).
Screening of Control Alleles
PCR reactions were performed in a 100-ml vol con-
taining 50 ng of DNA from CEPH controls, 400 ng each
of forward and reverse primers, 200 mM dATP, dTTP,
dGTP, and dCTP (Pharmacia), 50 mM KCl, 10 mM Tris-
HCl (pH 8.3), 1.5 mM MgCl2, 0.01% gelatin, and 0.6
U of AmpliTaq polymerase (PE Biosystems). After an
initial denaturation step of 94C for 5 min, reactions
were cycled at 94C for 30 s, 60C for 30 s, and 72C
for 30 s for 35 cycles, with a final extension step of 72C
for 10 min in a PE Biosystems 9600 thermal cycler.
For the digestions, 5 ml of the PCR product was di-
gested with an enzyme, according to the protocol sup-
plied with each enzyme, in a 15-ml vol. Ten microliters
of the restriction digestion were loaded onto a 3% aga-
rose gel and electrophoresed for 2 h.
Mitochondrial Genome Analysis
A PCR ApaI restriction-site assay was used to screen
for the mitochondrial tRNA Leu (UUR) ArG (nucleo-
tide 3243) mutation (Goto et al. 1990), which has been
associated with maternally transmitted diabetes and
deafness (van den Ouweland et al. 1992). The final cycle
of PCR was labelled with P33 dATP, permitting detection
of the mutation at levels of heteroplasmy !1%. Blood
DNA was also screened for the 11778ArT and
3460ArT mutations associated with Leber’s hereditary
optic neuropathy (LHON) with use of allele-specific
PCR (Norby 1993).
mtDNA was also analyzed for major rearrange-
ments by long-range PCR (Li et al. 1995). PCRs were
performed in a final vol of 50 ml with 5 pmol each of
primers L1 (nucleotides 2695–2720) and H3 (nucle-
otides 16459–16436), 2.5 mM MgCl2, 250 mM of
each dNTP, 1 # Bio-Optiform 111 buffer (Bioline),
and 1.5 of U Bio-X-ACT Taq polymerase (Bioline).
PCRs were hot started at 80C with the addition of
20–50 ng of DNA and were denatured at 95C for 10
s and at 68C for 10 min, plus 30 s for each subse-
quent cycle (25 cycles). PCR products were electro-
phoresed on 0.7% Seakem agarose gels.
Results
Clinical Data
The clinical features of our cohort have been described
elsewhere by Barrett et al. (1995), and family trees and
linkage data have been presented by Collier et al. (1996).
Ascertainment bias was negated by use of the minimum
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ascertainment criteria of juvenile-onset diabetes mellitus
and optic atrophy. The ascertainment criteria were val-
idated by comparison of index with secondary patients.
All secondary patients also had diabetes mellitus and
optic atrophy; there was no significant difference in the
ages at onset or prevalence of complications between
index and secondary patients ( ). It was, therefore,P 1 .02
concluded that intrafamilial variability was not signifi-
cant in our cohort. Thirty subjects from 19 families in
this cohort were investigated for the current study. The
clinical details are summarized intable 1. The families
included in our genetic-linkage study are indicated by
the original family letter (Collier et al. 1996). All families
were of white U.K. origin except one family from Pak-
istan (family 11) and one family of mixed African/Arabic
descent (family 1[B]). This last family was the only one
that showed psychiatric signs; these included short-term
memory loss, hallucinations, endogenous depression,
emotional lability, and presenile dementia reported in a
deceased affected sibling. There was no evidence of psy-
chiatric illness in the other patients as judged from the
patient history, formal examination, or hospital records.
Magnetic-resonance imaging (MRI) scans were avail-
able for six patients, including the two siblings with
psychiatric signs (patients 2016, 2017, 2054, 7508,
7509, and 1945). In all six cases, the MRI scans revealed
generalized brain atrophy, especially in the cerebellum,
medulla, and pons; absence of signal in the posterior
pituitary; and reduced signal in the optic nerve.
Mutation-Analysis Data
The WFS1 cDNA sequence (GenBank accession num-
ber AF084481) was compared with and found to be
almost identical to the Wolframin cDNA sequence
(GenBank accession number Y18064). Eight differences
were found: seven were silent mutations, and the re-
maining GrA conversion resulted in a conservative sub-
stitution of 611HrR (fig. 1). In our study, sequences
obtained from patients were compared with the WFS1
sequence and with normal control chromosomes. The A
of the ATG of the initiator Met codon was denoted as
“nucleotide 1.” Sequencing of exons 2–8 (exon 1 is
noncoding) revealed mutations in all the familial patients
and in eight of the nine sporadic patients (table 2). In
one of the singleton patients (patient 1519), only one
mutation was identified. The majority of mutations were
nonsense or frameshift mutations (fig. 1) and suggested
WFS1 loss-of-function mutations as the cause of Wolf-
ram syndrome. The effect, if any, of these mutations on
mRNA transcript stability is not known.
Deletions
Single-bp deletions resulting in frameshifts and pre-
mature STOP codons were detected in five patients (table
2). A single-bp deletion of nucleotide 1549 in exon 8
was found as a heterozygous mutation in two families
(family 2[D] and family 10[W]), resulting in a frameshift
at codon 517 (Arg) and an early STOP codon, predicting
a truncated protein of only 521 amino acids (aa). Nu-
cleotide 2433 in exon 8 was deleted from both alleles
in family 6(I), resulting in a frameshift and a truncated
protein of 861 aa. The parents of this affected subject
were known to be consanguineous. Family 4(F) was
found to have a 14-bp deletion, resulting in 537CysrX
and early termination.
In-frame deletions were also detected: a 3-bp deletion,
nucleotides 1060–1062, in exon 8, in family 16 resulted
in the heterozygous loss of Phe354. Another in-frame
deletion (loss of Val415, nucleotides 1243–1245 in exon
8) was found in family 9(S). A heterozygous 6-bp de-
letion was found in exon 8 of family 3(E) (nucleotides
1698–1703) with the loss of codons 567–568 (Leu and
Phe). A 4-bp heterozygous deletion of nucleotides
2648–2651 was found in families 8(T), 10(W), 12, and
18 (fig. 2A and 2B). This deletion resulted in a frame-
shift, a readthrough of the normal STOP codon, and
termination at a downstream UAG at nucleotide 2850
(normal sequence) (fig. 2A). The mutant protein encoded
by this sequence is 949 aa long, with a predicted mo-
lecular mass of 106 kD (fig. 2B) (calculated with pro-
gram pI/MW [ExPASy web site]).
Substitutions
Several nonsense mutations were detected in the fam-
ilies studied. A nonsense mutation in exon 4, 136GlurX
(CAGrUAG), was found in family 1(B) (fig. 3A). This
mutation was present in all three affected patients as a
homozygous mutation and predicted a severely trun-
cated protein product of 135 aa, which lacked the trans-
membrane domains and the hydrophilic carboxy tail.
Affected members of family 2(D) were found to be het-
erozygous for the 1944GrA substitution, which resulted
in 648TrprX and loss of the hydrophilic carboxy ter-
minus (fig. 1). A GrA substitution at nucleotide 1,433,
resulting in 478TrprX, was found in families 4(F), 5(H),
and 16 (fig. 3B). The resulting predicted truncated pro-
tein product encodes for the hydrophobic amino ter-
minus and for only four of the predicted transmembrane-
spanning domains (fig. 1). Family 5(H) was found to
harbor a second nonsense mutation, 2002CrT, which
resulted in 668GlurX (fig. 1). Patients from family 7(J)
had a 906CrA substitution that resulted in 302TyrrX
(fig. 1). A substitution of 1999CrT in family 8(T), and
the corresponding GlnrX mutation at aa residue 667,
predicted a protein product with the majority of the
carboxy tail deleted (fig. 1). The affected patient in fam-
ily 12 was found to be heterozygous for a 2254TrG
substitution that converted 752GlurX. This mutation
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Table 2
Mutations in the WFS1 Gene
Family (Patient No[s].)a Exon Nucleotide Change Amino Acid Changeb Type of Mutation
1(B)a (7509, 7508, 1558) 4 406CrT Q136X Nonsense
2(D) (1270, 1271) 8 1549del (C); 1944GrA Del517fs/ter521;
W648X
Frameshift/truncation; nonsense
3(E) (1547, 1588) 8 1698-1703del (CTCTTT); 1309GrC Del567-568LF;
G437R
Deletion; missense
4(F) (5534, 5533) 8 1611-1624del (CTTCATGTGGTGTG);
1433GrA
Del538-542fs/ter537;
W478X
Frameshift/truncation; nonsense
5(H) (2781, 3304) 8 1433GrA; 2002CrT W478X; Q668X Nonsense; nonsense
6(I) (5284) 8 2433del (A) Del812fs/ter861 Frameshift/truncation
7(J) (2016, 2017) 8 906CrA; 2206GrA Y302X; G736S Nonsense; missense
8(T) (5216, 8277) 8 1999CrT; 2648-2651del (TCTT) Q667X; Del883fs/
ter949
Nonsense; frameshift/elongation
9(S) (7087, 7668, 7669) 8 1243-1245del (GTC) Del415V Deletion
10(W) (6032, 6031) 8 1549del (C); 2648-2651del (TCTT) Del517fs/ter521;
Del883fs/ter949
Frameshift/truncation;
frameshift/elongation
11 (1709) 8 2654CrT P885L Missense
12 (3328) 8 2648-2651del (TCTT);2254GrT;
2100GrT
Del883fs/ter949;
E752X; W700C
Frameshift/elongation;
nonsense; missense
13 (7944) 8 874CrT; 817GrT P292S; E273X Missense; nonsense
14 (1519) 8 2254GrT; ND E752X; ND Nonsense: ND
15 (5461) 8 505GrA; 2068TrC; 887TrG E169K; C690R;
I296S
Missense; missense; missense
16 (5514) 8 1060-1062del (TTC); 1433GrA Del354F; W478X Deletion; nonsense
17 (4815) 8 817GrT; 1504ins24bp E273X; 502Sins/8aa Nonsense; in-frame insertion
18 (1945) 8 2648-2651del (TCTT) Del883fs/ter949 Frameshift/elongation
19 (2054) ND ND ND ND
NOTE.—Abbreviations: del = deletion, fs = frameshift, ter = termination, and ND = none detected.
a Family letters refer to those in Collier et al. (1996).
b Amino acids are given in single-letter code.
was also found in family 14 (table 2). A 273GlurX,
caused by the 812TrG mutation, was also found in two
of the families studied (families 13 and 17).
A homozygous missense mutation was found in
the affected patient from family 11 (885ProrLeu
[CCArCUA]). This patient had consanguineous par-
ents. Other missense mutations were present as hetero-
zygous mutations in several families: 437GlyrArg in
family 3; 700TrprCys in family 12; 292ProrSer in fam-
ily 13; and 169GlurLys, 296IlerSer, and 690CysrArg
in family 15. These missense mutations were not present
in 128 CEPH control chromosomes.
Noncoding Polymorphisms
Polymorphisms that did not code for an aa change or
that resulted in conservative aa changes are summarized
in table 3. A substitution, 1832rG, resulted in a con-
servative 611HisrArg change in 54% of the individuals
analyzed. Another polymorphism, 997ArG with a re-
sulting 333IlerVal, was detected in 41% of individuals.
The functional significance of these changes is not
known at present.
Genotype-Phenotype Analysis
The data were analyzed for genotype-phenotype re-
lationships, and several interesting cases were noted. The
three affected subjects analyzed in family 1(B) carried a
homozygous nonsense mutation in exon 4. This pre-
dicted a severely truncated protein of 135 aa, deleting
the transmembrane and carboxy-terminal domains. The
affected individuals in this family suffered severe psy-
chiatric complications. These complications developed
when the patients were in their 30s and included short-
term memory loss, emotional lability, hallucinations, and
endogenous depression. This family was a large consan-
guineous pedigree of African/Arabic origin, with affected
individuals in two separate branches of the family. An
affected older sister of the affected brothers in this study
had died at age 39 years, after admission, in her 20s, to
hospital when she was given a diagnosis of presenile
dementia, endogenous depression, and frequent
hallucinations.
The affected subject in family 18 (patient 1945) de-
veloped central respiratory failure at age 16 years and
required a permanent tracheostomy. MRI demonstrated
severe brain-stem atrophy. Sequencing analysis revealed
a homozygous 4-bp deletion, resulting in a frameshift
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Figure 3 Nonsense mutations in patients 1558 and 5514. Exon 8 DNA was amplified by PCR, purified, and sequenced on an ABI 377
automated sequencer. A, representative electropherograms from a normal control and from patient 1558 (family 1[B]) harboring a homozygous
CrT substitution that results in Q136X and premature termination of the protein. B, representative electropherograms of the reverse complement
sequence of residues 1421–1443. Patient 5514 carries the heterozygous nonsense mutation, 1433CrT, and W478X, compared to the normal
control.
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Table 3
Polymorphisms
Nucleotide Change Amino Acid No. of Alleles (%)a
1831ArG H611R 29/54 (54)
1185TrC V395V 27/54 (50)
2433ArG K811K 24/54 (44)
997ArG I333V 22/54 (41)
2565GrA S855S 19/54 (35)
684GrC R228R 14/54 (26)
1500TrC D500D 12/54 (22)
1023CrT F341F 7/54 (13)
1725CrT A575A 6/54 (11)
2322GrA K774K 5/54 (9)
2292CrT P764P 2/54 (4)
1761GrT R587R 2/54 (4)
1367CrA R456R 1/54 (2)
993CrT F331F 1/54 (2)
a Frequency of polymorphism is calculated as the num-
ber of affected alleles, as a percentage of the total number
of alleles.
and readthrough, predicting a chimeric protein of 949
aa (fig. 2). The patient had an older sister with Wolfram
syndrome who had died at age 28 years from brain-stem
atrophy and central respiratory failure. Five other pa-
tients from three families (families 8, 10, and 12) in our
cohort were heterozygous for the 4-bp deletion; how-
ever, central respiratory failure was not observed in these
patients.
The affected individual in family 11 had a homozy-
gous missense mutation at codon 885 (ProrLeu), 5 aa
from the carboxy terminus. This patient has a mild phe-
notype and has not yet developed diabetes insipidus,
renal involvement, or neurological abnormalities. His
deafness is mild and he does not require a hearing aid.
The spread of mutations was compared between fam-
ilies in which symptoms developed at an earlier age (5
years) and those in which symptoms developed at a later
age (6 years). There was no obvious difference in the
proportion of different mutations between the two
groups.
mtData
Lymphocyte-derived DNA from all patients was
screened for the mitochondrial tRNA Leu 3243 muta-
tion and for the 11778 and 3460 mutations associated
with LHON. No mutations were found in this cohort.
In addition, lymphocyte-derived DNA was examined for
the presence of major mitochondrial rearrangements, in-
cluding deletions, as outlined above. No rearrangements
were found.
Discussion
Our study presents detailed clinical and mutation-
analysis data on the largest cohort of patients with Wolf-
ram syndrome studied to date. A total of 30 patients
from 19 kindreds were screened for mutations in the
WFS1 gene and in their mtDNA. WFS1 gene mutations
were identified on both alleles in 28 of 30 patients and
on one allele of 1 patient (patient 1519). This confirms
the genetic homogeneity of this disorder in our popu-
lation. We identified 24 different mutations, 23 of which
were novel, comprising 8 missense mutations, 8 non-
sense mutations, 3 in-frame deletions, 1 in-frame inser-
tion, and 4 frameshift mutations. A nonsense mutation,
W648X, identified in affected individuals from family
3(E), had been previously reported (Inoue et al. 1998).
There was only one patient (patient 2054, family 19) in
whom no mutations were identified. The possibility of
mutations in the promoter or intronic sequences was not
addressed, and this possibility may explain the disease
manifestation in this patient. Of the 28 patients with
Wolfram syndrome for whom both mutations were iden-
tified, 19 were compound heterozygotes for two differ-
ent mutations. This has been reported in many other
autosomal recessive conditions, including ataxia-telan-
giectasia, in which most patients are compound heter-
ozygotes for truncated proteins (Concannon and Gatti
1997). No evidence of pathogenic mtDNA mutations
was detected in our cohort of patients. The mt3243 mu-
tation in tRNA Leu (UUR), associated with diabetes mel-
litus and deafness, was absent, and no major rearrange-
ments of mtDNA were found in lymphocyte DNA.
To identify any possible mutational hot spots in the
WFS1 protein sequence, we combined our data with
results from two other reports (Inoue et al. 1998; Strom
et al. 1998). The frequency of mutations was plotted
against aa residues (fig. 4). Although the absolute num-
bers of patients examined is still small, we noted that
the majority of frameshifts and nonsense mutations lo-
calized to the predicted transmembrane domains of the
protein. Mutations resulted in loss of the carboxy tail
in 28 (47%) of 60 chromosomes analyzed, and an ad-
ditional 7 (12%) of 60 chromosomes had a 4-bp deletion
resulting in a predicted protein of 949 aa with a chimeric
carboxy terminus. Missense mutations were identified
on 13 (22%) of 60 chromosomes and were not observed
in a panel of 128 CEPH chromosomes. There was no
obvious common mutation in our families or in those
reported elsewhere. A 4-bp deletion at position 2648
was found in four of the U.K. families (families 8[T],
10[W], 12, and 18); however, genotyping across the
WFS1 region on 4p did not reveal a common haplotype
in the two families reported elsewhere (families T and
W; Collier et al. 1996). The lack of common mutations
and the presence of multiple private mutations imply
that screening of the WFS1 gene will not be straight-
forward and will require sequence analysis of exon 8
and, possibly, of other exons if mutations are not
identified.
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Figure 4 Clustering of deletions and nonsense mutations in the transmembrane domain of WFS1. Mutation-screening data from the
present study and two other studies (Inoue et al. 1998; Strom et al. 1998) were combined and plotted as frequency (number of patients) of
mutation against aa residue. Blackened bars represent deleted residues or positions of nonsense mutations, and unblackened bars represent
missense mutations. A linear schematic of the Wolframin protein is depicted below the graph, with the transmembrane domains denoted by
blackened boxes.
The detailed clinical data on our cohort of patients
enabled us to investigate whether particular mutations
were associated with common clinical patterns. Family
1(B) carried a homozygous mutation predicting a se-
verely truncated protein. This family has all the main
complications of Wolfram syndrome, including psychi-
atric complications. This phenotype may be due to com-
plete absence of any residual WFS1 activity or to ab-
errant function of the short 136 aa mutant protein.
Alternatively, the affected members may have all the
complications because they have lived long enough to
develop them. It is also possible that the mutation may
be in linkage disequilibrium with a locus for bipolar
affective disorder on chromosome 4p (Blackwood et al.
1996). This has been observed for the bipolar locus and
the gene for Darier disease on chromosome 12q (Crad-
dock et al. 1993).
The affected subject from family 18 (patient 1945),
with severe brain-stem atrophy, was homozygous for a
4-bp deletion, predicting an elongated protein (949 aa).
Given that severe respiratory involvement was observed
only in this patient and his sister, we speculate that this
phenotype is associated with aberrant function of the
chimeric 949 aa WFS1 protein; however, at present there
are no functional data to support this speculation. The
affected individual from family 11 had a homozygous
missense mutation at codon 885 and a mild phenotype.
He may be too young to have developed other compli-
cations. Alternatively, this carboxy-terminal missense
mutation may disrupt only a limited spectrum of WFS1
function.
Our characterization of the spectrum of mutations in
Wolfram syndrome now allows us to offer genetic testing
to unaffected younger siblings in Wolfram families. We
previously estimated the chance of Wolfram syndrome
manifesting itself in an affected individual by their 15th
birthday at ∼95% (Barrett et al. 1995). We now have
the potential to provide reassurance for siblings of af-
fected patients at a much earlier age. Heterozygote car-
riers of the Wolfram gene are reported to be 26 times
more likely to require hospitalization for psychiatric ill-
ness (Swift et al. 1998) and to have an increased prev-
alence of diabetes mellitus (Fraser and Gunn 1977). It
may be possible to screen populations with psychiatric
illness and diabetes mellitus for carriers of these muta-
tions. The obvious candidates include patients with bi-
polar depression, for which a locus has been mapped to
chromosome 4p (Blackwood et al. 1996), and patients
with type 2 diabetes mellitus. Our cohort includes an
excess of families in which relatives of affected patients
have type 2 diabetes. Patients with type 2 diabetes share
two characteristics with Wolfram diabetics: they do not
usually have evidence of autoimmune insulitis, and they
usually have an element of insulin deficiency as well as
insulin resistance.
The aim of the present study was to sequence and
characterize the WFS1 gene in a large cohort of Wolfram
patients and to determine any genotype-phenotype re-
lationships. All except two patients had mutations on
both alleles of their WFS1 gene. Even though the func-
tion of the WFS1 protein is not yet known, it is likely
that the cytoplasmic carboxy terminus of WFS1 is in-
teracting with other, as yet unidentified, proteins. Mu-
tation or deletion of the carboxy-terminal domain could
disrupt these interactions and, hence, protein function.
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Studies are currently under way to investigate the effects
of these mutations on protein function.
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